Daily Cardiology Research Analysis

HOPE-3 randomized 106 participants with advanced Duchenne muscular dystrophy to quarterly intravenous deramiocel or placebo. At 12 months, the total Performance of the Upper Limb 2.0 score favored deramiocel by 4.55 percentage points, with a 95% confidence interval of 0.47-8.63 and P=0.029. The treatment was similarly safe to placebo and represents phase 3 evidence for a heart-derived allogeneic cardiosphere-derived cell therapy affecting both skeletal and cardiac disease.

Impact: This is a multicenter, double-blind phase 3 trial demonstrating a statistically significant functional benefit from an emerging cellular therapy in a progressive disease with major cardiac and skeletal muscle involvement. The findings support a potentially disease-modifying treatment strategy that is not dependent on the patient's precise causal mutation.

Clinical Implications: Quarterly outpatient deramiocel may become a treatment option for patients aged 10 years or older with advanced Duchenne muscular dystrophy if findings are confirmed by regulatory review and longer-term follow-up. Cardiac surveillance remains important because the disease includes progressive cardiomyopathy, even when the principal measured benefit is skeletal muscle function.

Future Directions: Longer follow-up should determine whether deramiocel alters the trajectory of cardiomyopathy, preserves ambulatory and upper-limb function over several years, and improves survival. Studies should also evaluate optimal treatment timing, biomarkers of response, and comparative effectiveness against contemporary Duchenne muscular dystrophy standards of care.

This investigator-initiated trial randomized 984 adults with echocardiographically confirmed patent foramen ovale and frequent migraine to aspirin, clopidogrel, rivaroxaban, or metoprolol for 12 weeks. Responder rates were 61.7% for aspirin, 66.8% for clopidogrel, 78.4% for rivaroxaban, and 61.8% for metoprolol; all antithrombotic agents were non-inferior to metoprolol, and rivaroxaban was superior. No major bleeding events occurred during the treatment period.

Impact: The trial directly tests a clinically relevant treatment question at the intersection of structural cardiology, thrombosis, and neurology in a large, multicenter population. Its finding that rivaroxaban produced a higher migraine response rate than metoprolol may influence future treatment selection, although longer-term safety and confirmation in broader populations are needed.

Clinical Implications: In adults with patent foramen ovale and frequent migraine, antithrombotic therapy may be considered as an alternative preventive strategy when clinically appropriate. The findings do not justify routine anticoagulation solely for migraine because bleeding risk, PFO anatomy, stroke history, and individual cardiovascular indications must be incorporated into shared decision-making.

Future Directions: Future trials should compare antithrombotic strategies with contemporary migraine preventives over longer periods, stratify participants by PFO shunt characteristics and embolic risk, and assess whether selected subgroups derive sufficient benefit to justify anticoagulation. Comparative studies with PFO closure would also be informative.

This ancillary generalized pairwise comparison analysis evaluated 194 patients randomized in CASTLE-HTx to catheter ablation plus guideline-directed medical therapy or medical therapy alone. At 3 years, 61.6% of patient pairs favored ablation versus 26.4% favoring medical therapy, yielding a restricted net treatment benefit of 35.3% and win odds of 2.09, both favoring ablation. The benefit was mainly driven by lower all-cause mortality and fewer hospitalizations for worsening heart failure.

Impact: The study addresses a population with extremely limited therapeutic options and high mortality, where standard rhythm-control strategies are often considered insufficient. By showing a large hierarchical treatment benefit in a randomized end-stage heart failure population, it strengthens the case for early ablation rather than reserving the procedure for late-stage rescue.

Clinical Implications: For selected patients with end-stage heart failure and atrial fibrillation, early catheter ablation in addition to guideline-directed medical therapy should be considered before irreversible deterioration, ventricular assist device implantation, or transplantation. Patient selection, procedural risk, comorbidity burden, and transplant-center expertise remain essential.

Future Directions: Larger multicenter trials should evaluate the optimal timing of ablation, effects across heart-failure phenotypes and left ventricular ejection fraction ranges, and interaction with transplantation and mechanical circulatory support pathways. Long-term assessment of atrial fibrillation burden, quality of life, and procedural complications is also needed.